

2023 Notice of Annual General Meeting

BRISBANE, AUSTRALIA, 13 October 2023: AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**) has today released its 2023 Notice of Annual General Meeting (**AGM**).

AnteoTech's 2023 AGM will be held in-person on Tuesday, 14 November 2023 at 10:00am (Brisbane time) at Rydge's South Bank, 9 Glenelg St, South Brisbane. Shareholders will be able to view a live broadcast of the meeting at <https://www.conferenceonline.com.au/anteotechagm2023>, but will not be able to participate online.

Attached are copies of documents relating to the 2023 AGM, including the Chairman's letter to shareholders, Notice of Meeting and Proxy Form.

This announcement has been authorised for release by the Board.

- ENDS -

Media and investor enquiries: Friederike Graser, on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - AnteoTech Ltd (ASX:ADO)

AnteoTech is a revenue stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X™, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry, with first revenues targeted for late 2023 from our Brisbane based commercial plant. The portfolio includes a proprietary high silicon anode in late-stage development, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter ([@AnteoTech_](https://twitter.com/AnteoTech_)), LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

13 October 2023

Dear Shareholder

We are pleased to invite you to the 2023 Annual General Meeting (the **AGM**) of AnteoTech Ltd (**AnteoTech**) on Tuesday, 14 November 2023 at 10am Brisbane time (11am Sydney/Melbourne time). The AGM will be held at Rydges South Bank, in Brisbane.

This year a live broadcast of the Annual General Meeting will be available at: <https://www.conferenceonline.com.au/anteotechagm2023>. Shareholders will be able to view the Meeting live by watching the webcast, but will not be able to ask questions, make comments or vote through the webcast facilities.


The Notice of Meeting details the formal business to be dealt with at the AGM. You can access the Notice of Meeting and accompanying material online at the Company's website <https://www.anteotech.com/agm-2023>. A printed copy of the Notice of Meeting and accompanying material will not be sent to you unless you contact us at investors@anteotech.com.

Shareholders are invited to lodge questions in advance of the meeting by emailing questions to investors@anteotech.com by 5.00pm (Brisbane time) on Tuesday 7 November 2023. Common questions received from shareholders will be addressed during the meeting and also covered in the Chairman's address. The Chairman's address will be lodged with ASX shortly before commencement of the meeting.

For shareholders attending the meeting, there will be an opportunity to ask questions at the meeting as each resolution is being considered. In order for proxy appointments to be valid for the AGM they must be received no later than 10am (Brisbane time), on Sunday, 12 November 2023.

Thank you for your continued support of AnteoTech. We look forward to engaging with shareholders at the 2023 AGM.

Yours sincerely



Ewen Crouch AM
Chairman



(ABN 75 070 028 625)

NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT

Date of Meeting: Tuesday 14 November 2023
Time of Meeting: 10.00am (Brisbane time)
Place of Meeting: Rydges South Bank,
Room Rooftop South, Level Twelve
9 Glenelg Street
South Brisbane

Notice of Annual General Meeting

The Annual General Meeting of Shareholders of AnteoTech Ltd (**AnteoTech** or **Company**) for 2023 will be held at Rydges South Bank, Room Rooftop South, Level Twelve, 9 Glenelg Street, South Brisbane 4101, on Tuesday 14 November 2023 at 10.00am (Brisbane time). A live broadcast of the Annual General Meeting will be available at: <https://www.conferenceonline.com.au/anteotechagm2023>

Shareholders will be able to view the Meeting live by watching the webcast, but will not be able to ask questions, make comments or vote through the webcast facilities. Voting on the day of the Meeting will only be permissible by securityholders who are physically present at the Meeting. There will be no online voting on the day of the Meeting. For those not in attendance, voting should take place by appointed proxy within the prescribed timeframes.

The Explanatory Statement accompanying this Notice of Annual General Meeting provides additional information on matters to be considered at the Annual General Meeting. The Explanatory Statement and Proxy form part of this Notice.

The Directors have determined that pursuant to Regulation 7.11.37 of the *Corporations Regulations 2001* (Cth) the persons eligible to vote at the Annual General Meeting are those who are registered shareholders of the Company as at 10.00am (Brisbane time) on Sunday 12 November 2023.

Terms and abbreviations used in this Notice are defined in the Glossary in Annexure A to the Explanatory Statement.

BUSINESS

Financial and other matters

To receive and consider the financial reports of the Company and its controlled entities for the year ended 30 June 2023 and the related Directors' Report, Directors' Declaration and Auditors' Report.

NOTE: THERE IS NO REQUIREMENT FOR SHAREHOLDERS TO APPROVE THESE REPORTS.

Resolution 1

Remuneration Report

To consider and, if thought fit, to pass the following resolution as a non-binding resolution:

To adopt the Remuneration Report for the financial year ended 30 June 2023.

NOTE: THIS RESOLUTION IS ADVISORY ONLY AND DOES NOT BIND THE COMPANY OR DIRECTORS.

A voting exclusion statement applies to this resolution – see VOTING EXCLUSION STATEMENTS below.

Resolution 2

Re-election of Directors

To consider and, if thought fit, to pass each of the following resolutions as **separate ordinary resolutions**:

- a) *That Glenda McLoughlin be re-elected as a Director of the Company in accordance with the Company's Constitution.*
- b) *That Katherine Woodthorpe be re-elected as a Director of the Company in accordance with the Company's Constitution.*

Resolution 3

Grant of short term incentive Performance Rights under the Company's Equity Incentive Plan to the Managing Director & Chief Executive Officer

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

That approval is given for the grant of 2,820,000 Performance Rights under the Company's Equity Incentive Plan, to the Chief Executive Officer and Managing Director, David Radford, or his associated entities as set out in the Explanatory Statement to the notice of Meeting.

A voting exclusion statement applies to this resolution. Please see VOTING EXCLUSION STATEMENTS below.

Resolution 4

Grant of attaching Options to eligible Directors under the Share Purchase Plan

To consider and, if thought fit, to pass each of the following resolutions as **separate ordinary resolutions**:

- a) *That approval is given for the grant of 468,750 attaching options to Ewen Crouch or his associated entities under the Share Purchase Plan as set out in the Explanatory Statement to the Notice of Annual General Meeting.*
- b) *That approval is given for the grant of 468,750 attaching options to David Radford or his associated entities under the Share Purchase Plan as set out in the Explanatory Statement to the Notice of Annual General Meeting.*
- c) *That approval is given for the grant of 468,750 attaching options to Geoffrey Cumming or his associated entities under the Share Purchase Plan as set out in the Explanatory Statement to the Notice of Annual General Meeting.*
- d) *That approval is given for the grant of 468,750 attaching options to Glenda McLoughlin or her associated entities under the Share Purchase Plan as set out in the Explanatory Statement to the Notice of Annual General Meeting.*

A voting exclusion statement applies to each of these resolutions – see VOTING EXCLUSION STATEMENTS below.

Resolution 5

Grant of long term incentive Options to Directors

To consider and, if thought fit, to pass each of the following resolutions as **separate ordinary resolutions**:

- a) *That approval is given for the grant of 10,000,000 options to David Radford or his nominee as set out in the Explanatory Statement to the Notice of Annual General Meeting.*
- b) *That approval is given for the grant of 2,500,000 options to Ewen Crouch or his nominee as set out in the Explanatory Statement to the Notice of Annual General Meeting.*
- c) *That approval is given for the grant of 1,500,000 options to Geoff Cumming or his nominee as set out in the Explanatory Statement to the Notice of Annual General Meeting.*
- d) *That approval is given for the grant of 1,500,000 options to Glenda McLoughlin or her nominee as set out in the Explanatory Statement to the Notice of Annual General Meeting.*
- e) *That approval is given for the grant of 1,500,000 options to Katherine Woodthorpe or her nominee as set out in the Explanatory Statement to the Notice of Annual General Meeting.*

A voting exclusion statement applies to each of these resolutions – see VOTING EXCLUSION STATEMENTS below.

Resolution 6

Ratification of prior issue of Placement Options under Listing Rule 7.1

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

That the prior issue of 62,500,000 Options by the Company under the Placement, as detailed in the Explanatory Statement accompanying the Notice of Annual General Meeting, is approved and ratified.

A voting exclusion statement applies to this resolution. Please see VOTING EXCLUSION STATEMENTS below.

Resolution 7

Ratification of prior issue of Placement Shares under Listing Rule 7.1A

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

That the prior issue of 125,000,000 Shares by the Company under the Placement, as detailed in the Explanatory Statement accompanying the Notice of Annual General Meeting, is approved and ratified.

A voting exclusion statement applies to this resolution. Please see VOTING EXCLUSION STATEMENTS below.

Resolution 8

Ratification of prior issue of SPP Shares under Listing Rule 7.1

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

That the prior issue of 21,503,906 Shares by the Company under the Share Purchase Plan as detailed in the Explanatory Statement accompanying the Notice of Annual General Meeting, is approved and ratified.

A voting exclusion statement applies to this resolution. Please see VOTING EXCLUSION STATEMENTS below.

Resolution 9

Ratification of prior issue of SPP Options under Listing Rule 7.1

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

That the prior issue of 8,876,953 Options by the Company in furtherance of the Share Purchase Plan as detailed in the Explanatory Statement accompanying the Notice of Annual General Meeting, is approved and ratified.

A voting exclusion statement applies to this resolution. Please see VOTING EXCLUSION STATEMENTS below.

Resolution 10

Approval of 10% Placement Facility

To consider and, if thought fit, to pass the following resolution as a special resolution:

That approval is given for the issue of equity securities up to 10% of the issued capital of the Company calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Statement accompanying the Notice of Annual General Meeting.

A voting exclusion statement applies to this resolution. Please see VOTING EXCLUSION STATEMENTS below.

By order of the Board



Andrew Cook
Company Secretary
13 October 2023

AN EXPLANATORY MEMORANDUM ACCOMPANIES AND FORMS PART OF THIS NOTICE OF MEETING. SHAREHOLDERS SHOULD READ THESE DOCUMENTS IN FULL.

VOTING EXCLUSION STATEMENTS

In accordance with Listing Rule 14.11, the Company will disregard any vote cast in favour of the resolution set out below by or on behalf of the following persons:

Resolution 1 Adoption of Directors' Remuneration Report	A member of the Key Management Personnel (KMP) (being persons who are identified in the Remuneration Report) or their Closely Related Parties as well as any undirected votes given to a KMP as proxyholder.
Resolution 3 Grant of short term incentive Performance Rights under the Company's Equity Incentive Plan to the Managing Director & Chief Executive Officer	Mr David Radford, any of his associates, any person referred to in Listing Rule 10.14.1, 10.14.2, or 10.14.3 who is eligible to participate in the Equity Incentive Plan, and any of their associates.
Resolutions 4(a), 4(b), 4(c), and 4(d) Grant of attaching Options to eligible Directors under the Share Purchase Plan	In respect of each of resolutions 4(a), 4(b), 4(c), and 4(d) - the person who is to receive the Options (and their nominee, if applicable), or any associate of that person, and any other person who will obtain a material benefit as a result of the granting of the Options (except a benefit solely by reason of being a holder of Shares), and any of their associates.
Resolutions 5(a), 5(b), 5(c), 5(d), and 5(e) Grant of long term incentive Options to Directors	In respect of each of resolutions 5(a), 5(b), 5(c), 5(d), and 5(e) - the person who is to receive the Options (and their nominee, if applicable), or any associate of that person, and any other person who will obtain a material benefit as a result of the granting of the Options (except a benefit solely by reason of being a holder of Shares), and any of their associates.
Resolution 6 Ratification of prior issue of Placement Options under Listing Rule 7.1	Any person who participated in the issue of the Options under the Placement and any of their associates.
Resolution 7 Ratification of prior issue of Placement Shares under Listing Rule 7.1A	Any person who participated in the issue of the Shares under the Placement and any of their associates.
Resolution 8 Ratification of prior issue of SPP Shares under Listing Rule 7.1	Any person who participated in the issue of the Shares under the Share Purchase Plan and any of their associates.

Resolution 9 Ratification of prior issue of SPP Options under Listing Rule 7.1	Any person who participated in the issue of the Options under the Share Purchase Plan and any of their associates.
Resolution 10 Approval of 10% Placement Facility	A person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity) or an associate of the aforementioned persons.

The above voting exclusions do not apply to a vote cast in favour of the relevant resolution by:

- (a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions on the Proxy Form or given to the attorney to vote in that way;
- (b) the person chairing the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the chairman to vote on the resolution as the chairman decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

NOTES

The Notice of Meeting should be read in conjunction with the accompanying Explanatory Statement.

Proxy votes

A Shareholder entitled to attend and vote is entitled to appoint not more than two (2) proxies to attend and vote in their place. Where more than one (1) proxy is appointed, the appointment may specify the proportion or number of votes that the proxy may exercise, otherwise each may exercise half of the votes.

A proxy need not be a Shareholder. A form of proxy must be signed by the Shareholder or the Shareholder's attorney.

Proxies must reach the Company at least forty-eight (48) hours before the meeting at which the person named in the Proxy Form proposes to vote i.e. not later than 10.00am (Brisbane time) on Sunday 12 November 2023.

The address for lodgement of proxies is:

Delivery Address	Postal Address	Fax Number	Online
Link Market Services Limited* Parramatta Square Level 22, Tower 6 10 Darcy Street, Parramatta, NSW 2150 *during business hours (Monday to Friday; 9:00am - 5:00pm)	AnteoTech Ltd C/- Link Market Services Limited Locked Bag A14 Sydney South NSW 1235	+61 2 9287 0309	www.linkmarketservices.com.au

Power of Attorney

If a proxy is signed by a Shareholder's attorney, the Shareholder's attorney confirms that they have received no revocation of authority under which the proxy is executed and the authorities under which the appointment was signed or a certified copy thereof must also be received at least forty eight (48) hours before the meeting.

Bodies Corporate

A body corporate may appoint an individual as its representative to exercise any of the powers the body may exercise at meetings of a company's Shareholders. The appointment may be a standing one. Unless the appointment states otherwise, the representative may exercise all of the powers that the appointing body could exercise at a meeting or in voting on a resolution. The documentation evidencing such appointment should be produced prior to admission to the Meeting.

Questions for the Board

Shareholders are invited to lodge questions in advance of the meeting by emailing questions to investors@anteotech.com by 5.00pm (Brisbane time) on Tuesday 7 November 2023. Common questions received from shareholders prior to the meeting will be addressed during the meeting and may also be covered in the Chairman's address. The Chairman's address will be lodged with ASX shortly before commencement of the meeting.

Shareholders not in attendance and viewing the meeting via the webcast will not be able to ask questions, make comments or vote through the webcast facilities. For shareholders attending the meeting, there will be an opportunity to ask questions at the meeting as each resolution is being considered.

Questions for the Auditor

Under section 250PA of the Corporations Act, Shareholders may submit written questions for the auditor up to five business days before the date of the Meeting. Shareholders wishing to do so may send their questions to the Company at Unit 4, 26 Brandl Street, Eight Mile Plains, QLD 4113 or to Fax 07 32190553 or email at investors@anteotech.com, and the Company will pass them on to the auditor.

2023 Annual Report

Copies of the Company's 2023 Annual Report for the financial year ending 30 June 2023 comprising the Annual Financial Reports, Directors' Report and Auditor's Report of the Company and the Company's controlled entities will be distributed to those Shareholders requesting a physical copy of these documents. The Annual Report is able to be viewed at the Company's website at www.anteotech.com

Conduct of the Meeting

We are committed to ensuring that our shareholder meetings are conducted in a manner that provides those shareholders or their proxy holders who attend the meeting with the opportunity to participate in the business of the meeting in an orderly fashion.

To assist with this and to achieve the objectives of the meeting, we ask that shareholders be courteous and respectful to all shareholders and others attending the meeting by asking concise questions about the matters which are relevant to the business of the meeting.

The Chairman of the meeting will exercise his powers to ensure that the meeting is conducted in an orderly and timely fashion in the interests of all attending shareholders.

Explanatory Statement

INTRODUCTION

This Explanatory Statement has been prepared to assist Shareholders in considering the Resolutions set out in the Company's Notice of Meeting. This Explanatory Statement forms part of, and should be read in conjunction with, the Company's Notice of Meeting to be held on Tuesday 14 November 2023 at 10.00am (Brisbane time).

Terms used in this Explanatory Statement are defined in the Glossary in Annexure A to this Explanatory Statement.

FINANCIAL STATEMENTS

The Corporations Act requires that the Financial Report (including the Directors' Report, Financial Statements and the Audit Report) be laid before the Meeting. Although not requiring a vote of Members, an opportunity will be provided for Members to ask questions on the reports, including of the Company's auditor, relating to the Audit Report.

Shareholders may submit written questions for the auditor up to five business days before the date of the Meeting. Shareholders wishing to do so may send their questions to the Company at Unit 4, 26 Brandl Street, Eight Mile Plains, QLD 4113 or Fax 07 3219 0553 or email at investors@anteotech.com, and the Company will pass them on to the auditor.

RESOLUTION 1

Remuneration Report

General

The Remuneration Report is set out in the Directors' Report section of the Annual Report. The Annual Report is available to download on the Company's website, www.anteotech.com.

Under Section 250R(3) of the Corporations Act, the vote is advisory only and does not bind the Directors or the Company.

In summary the Remuneration Report:

- 1) explains the Board's policy for determining the nature and amount of remuneration of Key Management Personnel of the Company;
- 2) explains the relationship between the Board's remuneration policy and the Company's performance;
- 3) sets out remuneration details for each Key Management Personnel; and
- 4) details and explains any performance conditions applicable to the remuneration of Key Management Personnel.

Voting restrictions on Key Management Personnel and their proxies and Closely Related Parties

A voting exclusion statement in respect of Resolution 1 is set out in the Notice of Meeting.

Directors' Recommendation

Noting that each director has a personal interest in their own remuneration from the Company (as described in the Remuneration Report), each Director recommends that Shareholders vote in favour of adopting the Remuneration Report.

RESOLUTION 2 (a)

Re-election of Glenda McLoughlin as a Director

General

Glenda McLoughlin retires in accordance with the Constitution and, being eligible, offers herself for re-election as a director. Ms McLoughlin has been a Non-Executive Director of the Company since 1 September 2021. She is Chair of the Audit and Risk Committee and a Member of the Remuneration and Nomination Committee.

Ms McLoughlin has extensive commercial experience as a senior investment banker, commercial advisor and founder in the energy, infrastructure and technology sectors. She also has over 20 years' experience on listed company boards.

In her executive career she held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia.

In addition to her work in the energy sector, Ms McLoughlin has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Ms McLoughlin co-founded Metgasco Ltd (ASX:MEL), where she was Executive Director and Chief Financial Officer for eight years.

Ms McLoughlin has strong credentials in corporate governance with extensive experience as Chair of Audit and Risk Committees.

Past Directorships include: Senex Energy (ASX: SXY), Metgasco (ASX:MEL), Elk Petroleum (ASX:ELK) and the National Art School. She is currently Chair of SCECGS Redlands. Glenda is a Fellow of the Australian Institute of Company Directors.

Directors' Recommendation

The Directors (other than Ms McLoughlin) unanimously recommend that Shareholders vote in favour of the re-election of Ms McLoughlin.

RESOLUTION 2 (b)

Re-election of Katherine Woodthorpe AO as a Director

General

Dr Katherine Woodthorpe retires in accordance with the Constitution and, being eligible, offers herself for re-election as a director. Dr Woodthorpe has been a Non-Executive Director of the Company since 1 September 2021. She is a Member of the Audit and Risk Committee and, since 1 September 2023, Chair of the Remuneration and Nomination Committee.

Dr Woodthorpe is an experienced Chair and non-executive director serving for over 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has a strong track record in a broad range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science.

Dr Woodthorpe has been cited in various media as one of Australia's most influential people in innovation. She has sat on the boards of a number of healthcare companies including Ventracor and Sirtex Ltd.

For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Dr Woodthorpe holds a Bachelor of Science (Manchester Uni.) and Ph.D. (Chemistry, Leicester Uni, UK). Dr Woodthorpe is a Fellow of the Australian Institute of Company Directors.

Directors' Recommendation

The Directors (other than Dr Woodthorpe) unanimously recommend that Shareholders vote in favour of the re-election of Dr Woodthorpe.

RESOLUTION 3

Grant of short term incentive Performance Rights under the Company's Equity Incentive Plan to the Managing Director & Chief Executive Officer

General

Shareholders are asked to approve the grant of 2,820,000 Performance Rights (**Performance Rights**) to David Radford, under the Company's Equity Incentive Plan, in respect of his role as Managing Director and Chief Executive Officer of the Company, as part of a short term incentive to reward Mr Radford for the achievement of specified KPIs during the financial year to 30 June 2024 that contribute to the short term performance of the Company.

If the Performance Rights are approved and subject to the conditions set out below, Mr Radford will be issued up to 2,820,000 Shares in the Company.

Listing Rule 10.14

Under Listing Rule 10.14, the issue of equity securities to certain persons (including directors) requires the approval of the holders of ordinary securities. Assuming approval is obtained pursuant to Listing Rule 10.14, the Company is entitled to rely on Listing Rule 10.12, Exception 8, as an exception to any requirement that may otherwise apply requiring shareholder approval under Listing Rule 10.11. Similarly, approval will not be required under Listing Rule 7.1.

Shareholder approval is required for the grant of the Performance Rights because Mr Radford is Managing Director and Chief Executive Officer of the Company.

If Resolution 3 is passed, the Company will proceed to grant the Performance Rights to David Radford. If Resolution 3 is not passed, the Company will not grant those Performance Rights, and the Company may need to consider an alternative strategy to incentivise and reward David Radford for short to medium term performance.

Technical Information required by Listing Rule 10.15

a) Details of David Radford and the Performance Rights

- The Company intends to grant 2,820,000 Performance Rights to Mr Radford not later than 1 month after the date of the Meeting.
- His total remuneration package is \$495,399 (inclusive of superannuation).
- 2,211,200 Options have previously been granted to Mr Radford under the Equity Incentive Plan (with no consideration payable for their grant).

b) Overview and key terms of the Performance Rights

- *Entitlement:* Each Performance Right entitles Mr Radford to one fully paid ordinary share in the capital of the Company, which will be issued on the vesting of the Performance Right.
- *Consideration:* no consideration is payable for the grant of the Performance Rights, nor upon the vesting of the Performance Rights.
- *Vesting:* the Performance Rights vest upon meeting certain Key Performance Indicators (**KPIs**). The performance measures involve the use of annual performance objectives, metrics, performance appraisals and continuing emphasis on living the Company's values (and those of its controlled entities). The measures target areas the Board believes hold the greatest potential for expansion and profit and cover financial and non-financial measures. The KPIs for the Executive team (including David Radford) are summarised as follows:

- financial: revenues, cost management, non-dilutionary funding and/or completion of commercial agreements; and
 - non-financial: strategic goals set by each individual business unit and holistic company-wide performance criteria, including product development, project delivery, human resources, Workplace, Health & Safety, and technical outcomes.
- the number of Performance Rights that will vest will correspond with the percentage between 0-100 of the Boards assessment of the KPIs Mr Radford has achieved during the financial year to 30 June 2024. The assessment will be made during July and August 2024 and the Performance Rights will vest immediately following a Board resolution of percentage of KPIs achieved for the year. On vesting each vested Performance Right becomes one ordinary share in the Company.
 - The total equity incentives for the Managing Director and Chief Executive Officer equate to approximately 50% of his cash salary using the 5-day VWAP as of 30 June 2024. The 50% equity incentive will be split evenly between short-term and long-term incentives.

c) Other terms of Performance Rights

The rules of the Equity Incentive Plan otherwise apply in respect of the Performance Rights, with the key terms set out at Annexure B to this Explanatory Statement.

d) Reasons for grant of Performance Rights

The Company has agreed to grant the Performance Rights to David Radford, subject to Shareholder approval, for the following reasons:

- to incentivise him with short term KPIs so as to contribute to the overall performance of the Company;
- the grant of the Performance Rights has no immediate impact of dilution on the Shareholders and will only dilute Shareholders if the Performance Rights vest on achievement of the vesting conditions;
- the issue of the Performance Rights is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to David Radford;
- it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing Performance Rights on the terms proposed.

Details to be published

The Details of any Performance Rights granted under the Equity Incentive Plan to Mr Radford will be published in the annual report of the Company relating to the period in which they are issued, along with a statement that approval for the grant was obtained under Listing Rule 10.14.

Any additional persons who are covered by Listing Rule 10.14 who become entitled to participate in the issue of securities under the Equity Incentive Plan after this Resolution is approved and who were not named in this Notice of Meeting, will not participate until approval is obtained under that Listing Rule.

Directors' Recommendation

The Directors (other than Mr Radford) unanimously recommend that Shareholders vote in favour of Resolution 3.

RESOLUTION 4(a), 4(b), 4(c), and 4(d)

Grant of attaching Options to eligible Directors under the Share Purchase Plan

General

On 26 July 2023 the Company announced a Share Purchase Plan to eligible shareholders to raise up to \$2,000,000, in conjunction with the Placement announced at the same time (as described in Resolutions 6 and 7). The Shares were offered at an issue price of \$0.032 (3.2 cents) per Share (**SPP Shares**), with one free attaching unlisted Option for every two (2) SPP Shares subscribed for and issued under the Share Purchase Plan (**SPP Option**), being up to 31,250,000 Options (together, the **SPP Securities**).

Under the Share Purchase Plan, 21,503,906 SPP Shares were issued on 11 September 2023, together with the grant of 8,876,953 Options which were issued on 13 September 2023, raising \$688,125 (before costs). Of the \$688,125 raised, eligible Directors subscribed for \$120,000 of SPP Shares, representing the maximum amount that each eligible Director could subscribe for under the Share Purchase Plan.

Shareholders are asked to approve the grant of 468,750 SPP Options to each of the following Directors (or their associated entities) who, as at the Record Date specified in the Share Purchase Plan (being 25 July 2023) were Shareholders in the Company, but were unable to participate in the issue of the SPP Options, due to the requirements of Listing Rule 10.11:

- Resolution 4(a) – Ewen Crouch;
- Resolution 4(b) – David Radford;
- Resolution 4(c) – Geoffrey Cumming; and
- Resolution 4(d) – Glenda McLoughlin,

(**Shareholder Directors**). As at the Record Date Katherine Woodthorpe did not hold any Shares in the Company, only unexercised Options, hence she is not included as a Shareholder Director.

The ASX granted a waiver in respect of Listing Rule 10.11 to enable each of the Shareholder Directors to participate in the Share Purchase Plan with respect to the issue of SPP Shares, without Shareholder approval. The waiver did not extend to the issue of SPP Options to Shareholder Directors or the related entities. The Letter to Shareholders forming part of the Share Purchase Plan booklet foreshadowed that Shareholder approval would be sought for the issue of SPP Options to Directors or their related entities at the Company's next annual general meeting.

Each of the Shareholder Directors participated in the Share Purchase Plan to the full amount of \$30,000 each, and as such would have otherwise been entitled to 468,750 SPP Options each.

If the grant of SPP Options to Shareholder Directors is approved, then:

- those SPP Options will be granted to the Shareholder Directors; and
- each Shareholder Director (whose grant of SPP Options is approved) will be able to exercise their respective SPP Options to acquire Shares in the Company by paying the exercise price of \$0.064 (6.4 cents) per SPP Option.

Listing Rule 10.11

Under Listing Rule 10.11, the issue of equity securities to certain persons (including directors or their associated entities) requires the approval of the holders of ordinary securities, unless an exception under Listing Rule 10.12 applies. The exceptions under Listing Rule 10.12 are not applicable in respect of the SPP Options. Assuming approval is obtained pursuant to Listing Rule 10.11, the Company is entitled to rely on Listing Rule

10.11 for the grant of the Options, as well as Listing Rule 7.2, Exception 14, such that approval will not be required under Listing Rule 7.1.

If Resolutions 4(a), 4(b), 4(c), and 4(d) are passed, the Company will proceed to grant 468,750 SPP Options to the each of the Shareholder Directors.

If any of Resolutions 4(a), 4(b), 4(c), and 4(d) are not passed, the Company will not grant SPP Options in respect of the resolution or resolutions that were not passed, and the Shareholder Directors will not have any other claims against the Company in equity or for other compensation in respect of the Options that are not granted.

Details of proposed SPP Options and the relevant Directors

Director Name	Number of Options	Date(s) on or by which the Company will grant the Options
Ewen Crouch	468,750	Not later than 1 month after the date of the Meeting.
David Radford	468,750	
Geoffrey Cumming	468,750	
Glenda McLoughlin	468,750	

Key Terms of Options

Each SPP Option will be granted on the same terms as set out in the Prospectus dated 9 August 2023 and annexed to the Share Purchase Plan Booklet issued on 9 August 2023, including the following key terms:

- *Consideration*: nil cash consideration is payable for grant of the Options, as they are free attaching Options for every two (2) SPP Shares subscribed for by the respective Shareholder Director under the Share Purchase Plan.
- *Exercise Price*: \$0.064 (6.4 cents).
- *Expiry*: 12 September 2026, being 3 years from date of grant of the SPP Options to the other participants under the Share Purchase Plan on 13 September 2023.
- *Vesting Conditions*: Nil.
- *Issue of Shares*: Each Option on exercise (and payment of the exercise price) entitles the holder to one fully paid ordinary share in the capital of the Company.

Other Terms of SPP Options

The Shareholder Directors may have subscribed for the SPP Shares through an immediate family member, a family trust, a family company, or a self-managed superfund of which they are a beneficiary (**Associated Entity**). For any Shareholder Director who subscribed for their SPP Shares through an Associated Entity, the SPP Options will be granted to that Associated Entity.

Purpose of the grant of SPP Options

The purpose of the grant of the SPP Options is to enable the Shareholder Directors to participate in the Share Purchase Plan on the same terms and with the same benefits as the other subscribers to the Share Purchase Plan. Currently, the Shareholder Directors have each paid \$30,000 (the full subscription amount permitted under the Share Purchase Plan), subscribing for 937,500 SPP Shares. However, they have not received the benefit of being granted the free attaching SPP Options.

The grant of the SPP Options is not intended to remunerate or incentivise the Shareholder Directors, as they are offered on the same terms as they were to all other eligible Shareholders under the Share Purchase Plan.

Any funds raised through the exercise of SPP Options granted to the Shareholder Directors will be used for the same purposes as the other SPP Options, as set out in the Prospectus.

It is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing SPP Options on the terms of the Share Purchase Plan.

Directors' Recommendation

- The Directors (excluding Ewen Crouch) unanimously recommend that Shareholders vote in favour of Resolution 4(a).
- The Directors (excluding David Radford) unanimously recommend that Shareholders vote in favour of Resolution 4(b).
- The Directors (excluding Geoff Cumming) unanimously recommend that Shareholders vote in favour of Resolution 4(c).
- The Directors (excluding Glenda McLoughlin) unanimously recommend that Shareholders vote in favour of Resolution 4(d).

RESOLUTION 5(a), 5(b), 5(c), 5(d), and 5(e)

Grant of long term incentive Options to Directors

General

Shareholders are asked to approve the grant of long term incentive Options to Directors (or their associated entities) as follows:

- Resolution 5(a) – the grant of 10,000,000 Options to David Radford or his nominee;
- Resolution 5(b) – the grant of 2,500,000 Options to Ewen Crouch or his nominee;
- Resolution 5(c) – the grant of 1,500,000 Options to Geoff Cumming or his nominee;
- Resolution 5(d) – the grant of 1,500,000 Options to Glenda McLoughlin or her nominee; and
- Resolution 5(e) – the grant of 1,500,000 Options to Katherine Woodthorpe or her nominee.

Listing Rule 10.11

Please refer to the Explanatory Statement for Resolution 4 for information about Listing Rule 10.11.

If Resolutions 5(a), 5(b), 5(c), 5(d) and 5(e) are passed, the Company will proceed to grant the relevant number of Options to the each of the Directors.

If any of Resolutions 5(a), 5(b), 5(c), 5(d) and 5(e) are not passed, the Company will not grant Options in respect of the resolution or resolutions that were not passed.

Details of proposed Options and the relevant Directors

Director Name	Number of long term incentive Options to be granted	Current total remuneration package (including superannuation)	Number of Options previously issued	Average acquisition price (if applicable)	Date(s) on or by which the Company will grant the Options
David Radford	10,000,000	\$495,399	32,211,200	Nil	Not later than 1 month after the date of the Meeting.
Ewen Crouch	2,500,000	\$110,000	7,000,000	Nil	
Geoff Cumming	1,500,000	\$60,000	5,000,000	Nil	
Glenda McLoughlin	1,500,000	\$75,000	5,000,000	Nil	
Katherine Woodthorpe	1,500,000	\$75,000	5,000,000	Nil	

Key Terms of Options

Each Option will be granted on the following key terms:

- *Consideration*: No consideration is payable for issue of the Options.
- *Exercise Price*: the higher of:
 - \$0.048 (4.8 cents) – being 50% above the issue price of Shares under the Share Purchase Plan; and
 - 43% above the ASX closing price of Shares on the date that the Options are granted.
- *Expiry Date*: the earlier of 30 November 2026 or 6 months after the date that the relevant Director ceases to be a Director of the Company.
- *Exercise Period*: any time after vesting and prior to the expiry date.
- *Vesting Conditions*: the Options will vest (and become capable of exercise) as follows:
 - 50% of each Director's Options vest on 30 November 2024; and
 - 50% of each Director's Options vest on 30 November 2025.
- *Issue of Shares*: Each Option on exercise (and payment of the exercise price) entitles the holder to one fully paid ordinary share in the capital of the Company.

Other Terms of Options

Directors may nominate that their Options be granted to an immediate family member, a family trust, a family company, or a self-managed superfund of which they are a beneficiary.

The Options will not be granted under the Equity Incentive Plan. However, various provisions of the Equity Incentive Plan will be taken to apply in respect of the Options (relating to capital re-organisations, good and bad leaver provisions, change of control events, misconduct, and clawbacks), available on the Company's website, at www.anteotech.com.

Purpose of the grant of Options

The Company proposes to grant the Options to the Directors for the following reasons:

- The grant of the Options to the Managing Director and CEO financial year is to incentivise him to contribute to the medium to long term performance of the Company;
- the Board's remuneration policy is to remunerate Non-Executive Directors at market rates for comparable companies for time, commitment and responsibilities. The Nomination and Remuneration Committee of the Company determines payments to the Non-Executive Directors and reviews their remuneration annually, based on market practice, duties, and accountability. Cash remuneration payable to Non-Executive Directors has not been increased for the year. Independent external advice is sought when required;

- Director's fees payable to Non-Executive Directors are not linked to performance of the Company. However, to align Non-Executive Directors' interests with Shareholder interests, they are encouraged to hold Shares and will receive periodic grants of options (subject to Shareholder approval). These grants of options serve as both remuneration for the Non-Executive Directors, as well as to incentivise the relevant Non-Executive Directors to improve performance of the Company;
- the grant of Options to those Directors is part of the Board's strategy to retain talent and provide longer term incentive to the Directors;
- the Options are unquoted, therefore the grant of the Options has no immediate impact of dilution on the Shareholders;
- exercise of an Option requires payment of the exercise price which will then form part of the working capital to the Company;
- the deferred taxation benefit which is available to the respective Director in respect of a grant of Options is also beneficial to the Company as it means the respective option holders are not required to immediately sell the Options to fund a tax liability (as would be the case in an issue of Shares where the tax liability arises upon issue of the Shares), and they will instead continue to hold an interest in the Company (through their respective nominee if applicable); and
- it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing Options on the terms proposed.

Value of Options and basis for valuation

Shares (if any) attained by Directors, executives and employees through the granting of Options, are valued as the difference between market price of those Shares and the amount paid by the recipients.

The Options have been valued by an independent valuer using the Black Scholes option model and based on the assumptions set out below the Options were ascribed the following values:

Assumed grant date	14 November 2023				
Assumed expiry date	30 November 2026				
Share price at assumed grant date	\$0.027				
Exercise price	\$0.048				
Risk-free rate	3.975%				
Volatility	100%				
Fair value per Option	\$0.0146				
Recipient	David Radford	Ewen Crouch	Geoff Cumming	Glenda McLoughlin	Katherine Woodthorpe
Number	10,000,000	2,500,000	1,500,000	1,500,000	1,500,000
Total fair value (per Non-Executive Director)	\$145,960	\$36,490	\$21,894	\$21,984	\$21,984
Total fair value of Options	\$248,402				

Directors' Recommendation

- The Directors (excluding David Radford) unanimously recommend that Shareholders vote in favour of Resolution 5(a).
- The Directors (excluding Ewen Crouch) unanimously recommend that Shareholders vote in favour of Resolution 5(b).

- The Directors (excluding Geoff Cumming) unanimously recommend that Shareholders vote in favour of Resolution 5(c).
- The Directors (excluding Glenda McLoughlin) unanimously recommend that Shareholders vote in favour of Resolution 5(d).
- The Directors (excluding Katherine Woodthorpe) unanimously recommend that Shareholders vote in favour of Resolution 5(e).

RESOLUTIONS 6 AND 7

Ratification of prior issue of Placement Options and Placement Shares under listing rule 7.1 and 7.1A

General

On 26 July 2023 the Company announced a placement to institutional and sophisticated investors to raise \$4,000,000 (**Placement**) through the issue of 125,000,000 Shares at issue price of \$0.032 (3.2 cents) per Share (**Placement Shares**), with one free attaching unlisted Option for every two (2) Placement Shares subscribed for and issued, being 62,500,000 Options (**Placement Options**) (together, the **Placement Securities**).

On 2 August 2023, the Company issued the Placement Shares to raise \$4,000,000 (before costs) without prior Shareholder approval, pursuant to the Company's 7.1A mandate which was approved by the Shareholders at the Company's annual general meeting held on 17 November 2022.

On 13 September 2023, the Company issued the Placement Options without prior Shareholder approval, out of its annual 15% capacity under Listing Rule 7.1.

The Placement was not underwritten.

Resolutions 6 and 7 are as follows:

- Resolution 6 – that the Shareholders approve and ratify the prior issue of Placement Options pursuant to ASX Listing Rule 7.4; and
- Resolution 7 – that the Shareholders approve and ratify the prior issue of the Placement Shares pursuant to ASX Listing Rule 7.4.

ASX Listing Rule 7.1, 7.1A, and 7.4.

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period (**15% Capacity**).

Further, under Listing Rule 7.1A, an eligible entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase the 15% Capacity by an extra 10% to 25%. The Company obtained approval to increase its limit to 25% at the annual general meeting held on 17 November 2022.

The issue of the:

- Placement Options did not meet any of the available exceptions to Listing Rule 7.1 (being the subject of Resolution 6); and
- Placement Shares did not meet any of the available exceptions to Listing Rule 7.1A (being the subject of Resolution 7),

as set out in Listing Rule 7.2. Further, as the issue of each of the Placement Shares and Placement Options have not yet been approved by the Company's Shareholders, the Company uses up part of the combined 25% limit in Listing Rules 7.1 and 7.1A through these issues. This reduces the Company's Capacity to issue further equity securities without Shareholder approval under Listing Rules 7.1 and 7.1A for the 12 month period following the respective date of issue of each of the Placement Shares and the Placement Options.

In addition to the issue of the Placement Securities, the Company also issued SPP Shares and SPP Options under its 15% Capacity.

Listing Rule 7.4

Listing rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 or Listing Rule 7.1A (as applicable), and does not reduce the company's capacity to issue further equity securities without shareholder approval under those rules.

The Company wishes to retain as much flexibility as possible to issue additional securities in the future without having to obtain Shareholder approval for such issues under Listing Rules 7.1 and 7.1A. Accordingly, the Company is seeking Shareholder ratification pursuant to Listing Rule 7.4 in respect of:

- the Placement Options under Listing Rule 7.1; and
- the Placement Shares under Listing Rule 7.1A.

Technical information required by Listing Rule 14.1A

If either or both of Resolution 6 and Resolution 7 are passed, the Placement Options and/or the Placement Shares (as applicable) will be excluded in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, increasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the respective date of issue of the Placement Shares and the Placement Options.

If either or both of Resolution 6 and Resolution 7 are not passed, the Placement Options and/or the Placement Shares (as applicable) will be included in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the respective date of issue of the Placement Shares and the Placement Options.

Technical information required by Listing Rule 7.4 and 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in relation to Resolutions 6 and 7:

- the Placement Securities were issued to professional and sophisticated investors, including a number of new institutional investors in the Company. The recipients were identified by the Lead Manager of the Placement, Canaccord Genuity (Australia) Limited ACN 075 071 468;
- under the Placement:
 - 125,000,000 Placement Shares were issued on 2 August 2023; and
 - 62,500,000 Placement Options were issued on 13 September 2023;
- all of the Placement Shares were fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares;
- the issue price for the Placement Shares was \$0.032 (3.2 cents) per Share;
- the Company has received a total of \$4,000,000 as consideration for the Placement Shares;

- the Placement Options were granted on the same terms as the SPP Options:
 - *Consideration*: nil;
 - *Exercise Price*: \$0.064 (6.4 cents). Should the holders of the Placement Options choose to exercise the Placement Options in line with their terms and conditions, then the Company will receive up to \$4,000,000 for the exercise of those securities;
 - *Expiry*: 12 September 2026, being three years after the date of issue on 13 September 2023;
 - *Vesting Conditions*: nil;
 - *Ratio*: Placement Options were offered at a ratio of one free attaching Placement Option for every two Placement Shares subscribed for under the Placement;
 - *Quotation*: Placement Options are unlisted; and
 - *Participation*: only investors who participated in the Placement were entitled to subscribe for Placement Options.
- The Placement Securities were issued for the purpose of raising funds to be applied towards:
 - *Anteo XTM Commercialisation and Development Activities* – sales and marketing, and accelerating commercialisation for Anteo XTM and high silicon anodes in the battery sector;
 - *Anteo XTM* – further enhancement and integration into an extensive range of binder products;
 - *Anteo XTM Production Facility and Expansion* – commissioning the production facility with initial 20,000 litre annual capacity, and expansion of the production facility to 80,000 litre annual capacity;
 - *High Silicon Anode Development, Testing and Commercialisation* - premarket entry activities including research and development, IP establishment and protection, customer collaborations, and advanced testing equipment to accelerate development;
 - Future technology developments in the battery sector;
 - Commercial activities in life sciences;
 - Working capital; and
 - Costs of the capital raising.
- The Placement Securities were not issued under an agreement.

Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of each of Resolution 6 and Resolution 7.

RESOLUTIONS 8 and 9

Ratification of prior issue of SPP Options and SPP Shares under listing rule 7.1

General

As described in Resolution 4, on 26 July 2023 the Company announced the Share Purchase Plan to raise up to \$2,000,000 through the issue of Shares at issue price of \$0.032 (3.2 cents) per Share, with one free attaching unlisted Option for every two (2) SPP Shares subscribed for and issued.

On 11 September 2023, the Company announced the completion of the Share Purchase Plan. A total of \$688,125 was raised under the Share Purchase Plan, with 21,503,906 SPP Shares and 8,876,953 SPP Options issued without prior Shareholder approval, pursuant to Company's 15% annual capacity under Listing Rule 7.1.

Resolutions 8 and 9 are as follows:

- Resolution 8 – that the Shareholders approve and ratify the prior issue of the SPP Options pursuant to ASX Listing Rule 7.4; and
- Resolution 9 – that the Shareholders approve and ratify the prior issue of the SPP Shares pursuant to ASX Listing Rule 7.4.

Listing Rule 7.1

Please refer to the Explanatory Statement for Resolutions 8 and 9 for information about Listing Rule 7.1 (and also about Listing Rule 7.4).

Technical information required by Listing Rule 7.4 and 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in relation to Resolutions 8 and 9:

- the SPP Securities were issued to Shareholders who participated in the Share Purchase Plan;
- in furtherance of the Share Purchase Plan:
 - 21,503,906 SPP Shares were issued on 11 September 2023 (including 937,500 SPP Shares which were issued to the Shareholder Directors as described in Resolution 4, pursuant to the ASX waiver which was granted to allow Shareholder Director participation in the Share Purchase Plan in respect of SPP Shares only); and
 - 8,876,953 SPP Options were issued on 13 September 2023;
- no SPP Options have been issued to the Shareholder Directors – if all or any of Resolutions 4(a), 4(b), 4(c), and 4(d) are approved, then these SPP Options will be issued with Shareholder approval under Listing Rule 7.4, and are not included in the calculations for Resolution 8;
- all SPP Shares were fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares;
- the issue price for the SPP Shares was \$0.032 (3.2 cents) per Share;
- the Company has received a total of \$668,125 as consideration for the SPP Shares;
- the SPP Options were granted on the same terms as the SPP Options – refer to the Explanatory Statement for Resolutions 6 and 7;
- only Shareholders who participated in the Share Purchase Plan were entitled to subscribe for SPP Options.
- The SPP Securities were issued for the purpose of raising funds for the same purposes as the raising of the Placement Securities - refer to the Explanatory Statement for Resolutions 6 and 7.
- The SPP Securities were not issued under an agreement.

Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of each of Resolution 8 and Resolution 9.

RESOLUTION 10

Approval of 10% placement facility

General

Listing Rule 7.1A permits an "eligible entity" which has obtained shareholder approval by special resolution passed at an annual general meeting to issue "equity securities" (as defined in the Listing Rules and which includes shares and options to acquire shares) up to 10% of its issued share capital through placements over a maximum 12-month period after the relevant annual general meeting (the **10% Placement Facility**).

The issue of equity securities under the 10% Placement Facility would be in addition to the Company's ability to issue equity securities without Shareholder approval under Listing Rule 7.1. Broadly, Listing Rule 7.1 permits the Company to issue up to 15% of its issued equity capital without Shareholder approval over a 12-month period.

An "eligible entity" for the purposes of Listing Rule 7.1A is an entity that, as at the date of the relevant special resolution under that Rule, is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less. If the special resolution were voted on at the date of the Notice of Meeting, the Company would satisfy the eligible entity requirements, and the Directors believe that the Company will continue to satisfy those requirements on the date of the Meeting. If the Company was to not meet this requirement as at the date of the Meeting, then this Resolution 10 would be withdrawn.

Whilst the Company has no current intention to raise capital via this 10% Placement Facility, the Directors consider that it is prudent to have such a facility in place to provide flexibility on capital raising alternatives and corporate transactions should they be required in the coming 12 months.

The effect of Resolution 10 will be to allow the Directors to issue equity securities under Listing Rule 7.1A during a maximum period of 12 months after the Meeting without subsequent Shareholder approval and in addition to the Company's 15% placement capacity under Listing Rule 7.1.

Resolution 10 is a special resolution, which requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate shareholder, by a corporate representative).

Technical information required by Listing Rule 14.1A

If Resolution 10 is passed, the Company will be able to issue equity securities up to the combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.

If Resolution 10 is not passed, the Company will not be able to access the additional 10% capacity to issue equity securities, without Shareholder approval provided for in Listing Rule 7.1A and will remain subject to the 15% capacity limit in Listing Rule 7.1.

Additional Information

a) Equity Securities

Any equity securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of equity securities of the Company, being ordinary shares.

b) 10% Placement Period

Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A is valid from the date of the annual general meeting at which the approval is obtained and expires on the earlier to occur of:

- the date that is 12 months after the date of the annual general meeting;
- the time and date of the Company's next annual general meeting; and

- the date of the approval by shareholders of a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking).

c) Minimum Issue Price

The issue price of Shares issued under Listing Rule 7.1A must be not less than 75% of the VWAP (volume weighted average price) of Shares calculated over the 15 ASX trading days on which trades in Shares were recorded immediately before:

- the date on which the price at which the Shares are to be issued is agreed; or
- if the Shares are not issued within 10 ASX trading days of the date in above dot point, the date on which the Shares are issued.

d) Use of funds raised

The Company may seek to issue equity securities under the 10% Placement Facility for cash consideration only (under Listing Rule 7.1A), in which case the Company intends to use the funds raised for:

- further development of its existing products;
- to further progress the Company's corporate and commercialisation goals; and/or
- general working capital.

e) Risk of dilution

Any issue of Shares under the 10% Placement Facility will dilute the interests of Shareholders who do not receive any Shares under the issue.

There is a risk that:

- the market price for the relevant equity securities may be significantly lower on the date of the issue of the equity securities than on the date of the Meeting; and
- the equity securities may be issued at a price that is at a discount to the market price for the relevant equity securities on the issue date,

which may have an effect on the amount of funds raised by the issue of the equity securities.

The table below shows the potential dilution of existing Shareholders based on an issue price of \$0.031 per Share (being the market price of Shares as at 6 October 2023 and the current value for the variable "A" calculated in accordance with the formula in Listing Rule 7.1A(2) as at the date of the Notice of Meeting. The table also shows:

- two examples where variable "A" (being the number of Shares on issue) has increased, namely by 25% and by 100%. Variable "A" could increase as a result of issues of Shares that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and
- two examples of where the assumed issue price of \$0.031 per Share has changed: one, where it has decreased by 50% and two, where it has increased by 100%.

		50% decrease in Issue Price (\$0.0155)	Issue Price (\$0.031)	100% increase in Issue Price (\$0.062)
Current Variable "A" (2,196,442,432 Shares)	10 % voting dilution	219,644,243	219,644,243	219,644,243
	Funds raised	\$3,404,486	\$6,808,972	\$13,617,943
25% increase in current Variable "A" (2,745,553,040 Shares)	10 % voting dilution	274,555,304	274,555,304	274,555,304
	Funds raised	\$4,255,607	\$8,511,214	\$17,022,429
100% increase in current Variable "A" (4,392,884,864 Shares)	10 % voting dilution	439,288,486	439,288,486	439,288,486
	Funds raised	\$6,808,972	\$13,617,943	\$27,235,886

The table has been prepared on the following assumptions:

- There are currently 2,196,442,432 Shares on issue as at 6 October 2023.
- The issue price is \$0.031 being the closing price of the Shares on ASX on 6 October 2023.
- The Company issues the maximum number of equity securities available under the 10% Placement Facility.
- No options are exercised into Shares before the date of the issue of the equity securities.
- The 10% dilution reflects the aggregate percentage voting dilution against the issued share capital at the time of issue. This is why the dilution is shown in each example as 10%.
- The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder's holding at the date of the Meeting. All Shareholders should consider the dilution caused to their own shareholding depending on their specific circumstances.
- The table shows only the effect of issues of equity securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1.
- The issue of equity securities under the 10% Placement Facility consists only of Shares. If the issue of equity securities includes options, it is assumed that those options are exercised into Shares for the purpose of calculating the voting dilution effect on existing Shareholders.

f) Allocation policy

The Company's allocation policy for the issue of equity securities under the 10% Placement Facility is dependent on the prevailing market conditions at the time of any proposed issue. The identity of the allottees of the equity securities will be determined on a case-by-case basis having regard to the factors including but not limited to the following:

- the purpose of the issue;

- alternative methods of raising funds that are available to the Company, including a rights issue or other issue in which existing security holders can participate;
- the effect of the issue of the equity securities on the control of the Company;
- the circumstances of the Company, including, but not limited to, the financial situation and solvency of the Company; and
- advice from corporate, financial and broking advisers (if applicable).

The allottees of any equity securities that may be issued under the 10% Placement Facility have not been determined as at the date of the Notice but may include existing substantial Shareholders and/or new shareholders who are not related parties or associates of a related party of the Company. Further, if the Company is successful in acquiring new resources, assets or investments, it is likely that the allottees under the 10% Placement Facility will be the vendors of the new resources, assets or investments.

Previous approvals under Listing Rule 7.1A

In the 12 months preceding the date of this Meeting the Company issued 125,000,000 Shares, being the Placement Shares, under ASX Listing Rule 7.1A. The issue of those Placement Shares is the subject of Resolution 10. If Resolution 10 is approved by the Shareholders, then the 125,000,000 Placement Shares will not be taken to have been issued under Listing Rule 7.1A.

Voting Exclusion Statement

At the date of the Notice, the Company is not proposing to make an issue of equity securities under LR 7.1A, and the Company has not approached nor does it intend to approach any particular existing Shareholder or security holder or an identifiable class of existing security holders to participate in the issue of any equity securities. The Company has not formed an intention in relation to how it will decide which parties it might approach to participate in any issue of equity securities that might be made under the 10% Placement Facility. Assuming that remains the case at the time of the Meeting (which the Directors currently believe will be the case), no Shareholder's votes will be excluded under the voting exclusion in the Notice.

Listing Rules 7.1 and 7.1A

The ability of an entity to issue equity securities under Listing Rule 7.1A is in addition to the Company's 15% placement capacity under Listing Rule 7.1.

At the date of the Notice, the Company has the capacity to issue:

- 1) subject to Shareholder approval under Resolutions 6, 8 and 9, 329,466,364 equity securities under Listing Rule 7.1; and
- 2) subject to Shareholder approval under Resolutions 7 and 10, 219,644,243 equity securities under Listing Rule 7.1A.

The actual number of equity securities that the Company will have capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of the equity securities in accordance with the formula prescribed in Listing Rule 7.1A.2.

Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of Resolution 10.

ANNEXURE A – GLOSSARY

Annual General Meeting or **Meeting** means the meeting convened by this Notice.

ASIC means the Australian Securities and Investments Commission.

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

ASX Listing Rules or **Listing Rules** means the Listing Rules of ASX.

Auditor's Report means the auditor's report in the Financial Report.

Board means the board of directors of the Company.

Business Day means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day.

Chairman means the chairman of the Meeting.

Closely Related Party of a member of the Key Management Personnel means:

- (a) a spouse or child of the member;
- (b) a child of the member's spouse;
- (c) a dependent of the member or the member's spouse;
- (d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealings with the entity;
- (e) a company the member controls;
- (f) a person prescribed by the *Corporations Regulations* 2001 (Cth) for the purposes of the definition closely related party in the Corporations Act.

Company or **Anteo** means AnteoTech Ltd (ABN 75 070 028 625).

Constitution means the Company's constitution.

Corporations Act means the *Corporations Act 2001* (Cth).

Directors mean the directors of the Company.

Directors' Report means the annual directors' report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities.

Equity Incentive Plan means the Company's equity incentive plan, the material terms of which are summarised at Annexure B.

Explanatory Statement means the explanatory Statement accompanying the Notice.

Financial Report means the annual financial report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities.

Key Management Personnel has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated entity.

Notice means the Notice of Meeting accompanying this Explanatory Statement.

Option means an option to be issued a Share.

Placement means the issue of the Placement Shares on 2 August 2023 to institutional and sophisticated investors.

Placement Options means 62,500,00 Options.

Placement Shares means 125,000,000 Shares.

Prospectus means the prospectus of the Company issued on 9 August 2023 in respect of the SPP Options and the Placement Options.

Proxy Form means the proxy form for the General Meeting accompanying the Notice.

Resolutions means the resolutions set out in the Notice, or any one of them, as the context requires.

Share means a fully paid ordinary share in the capital of the Company.

Share Purchase Plan means the Company's Share Purchase Plan dated 9 August 2023.

Shareholders means a shareholder of the Company.

SPP Option means an Option granted in in furtherance of the Share Purchase Plan.

SPP Share means a Share issued in accordance with the Share Purchase Plan.

VWAP means volume weighted average price.

ANNEXURE B – MATERIAL TERMS OF EQUITY INCENTIVE PLAN

1. Eligibility

The Equity Incentive Plan is open to directors, employees and contractors of the Company that have satisfied the criteria of the Board from time to time are eligible, at the invitation and discretion of the Board to be issued equity incentives under the Plan ("**Eligible Person**").

The Board may allow an Eligible Person's nominee (i.e. an immediate family member, a corporate trustee of a superannuation fund of which Eligible Person is a director, or a company of which the Eligible Person or their immediate family members are shareholders or trustee of a trust) to be issued the equity incentives.

2. Offers

In determining whether to make offers, the Board may have regard to the persons length of service, their contribution to the AnteoTech group or other matter the Board considers relevant.

Equity incentives comprise shares, options or performance rights. An offer of these incentives may be made by the Board to an Eligible Person at any time and in any form, and may provide conditions, such as exercise price, vesting conditions and option period.

3. Restrictions

The Board must not issue Equity Incentives if the aggregate number of Equity Incentives issued to an Eligible Person under the Incentive Plan together with all other holdings of securities of all other Eligible Persons and shares issued under any other employee plan of the Company, during the previous three year period, would exceed 5% of the issued share capital of the Company.

Based on the Shares on issue as at the date of the Notice of Meeting (being 2,196,442,432 Shares) the maximum number of equity incentives that can be issued pursuant to the Equity Incentive Plan is 109,822,121.

4. Board's discretion and powers

The Board will administer the Equity Incentive Plan in accordance with the rules of the Plan ("**Rules**") (and any other terms prescribed by the Board for the operation of the Plan which are consistent with the Rules). The Board has absolute and unfettered discretion to:

- (d) act or refrain from acting pursuant to the Rules;
- (e) exercise any power or discretion under the Incentive Plan, including, determining which employees, Directors, executives or contractors are to be offered options under the Plan;
- (f) forfeit unvested shares, or lapse options or performance rights, in instances such as where an Eligible Person has been summarily dismissed, is in material breach of their duties or brings any company in the Anteo group into disrepute.
- (g) delegate its discretions and powers under the Plan;
- (h) amend, add or waive any provision of the Rules.

5. New Issues

Participants who hold options or performance rights are not eligible to participate in any new issue of securities to Shareholders unless they are entitled to exercise their options or performance rights and have done so before the relevant record date for the issue of securities.

Where a bonus issue of Shares occurs, the number of underlying Shares over which the option or performance right is exercisable will be increased as if the option or performance right been exercised before the record date for the bonus issue.

Where the Company undertakes a pro-rata Share issue or re-organises its capital, the exercise price of options of performance rights will be reduced or, the number of options or performance rights will be changed, as applicable, in accordance with the Listing Rules.

6. Good leaver and bad leavers

For any director, executive or employee who is a 'good leaver', any vested but unexercised options or performance rights can be exercised within 3 months of their leaving the Company. For Eligible Persons who are 'bad leavers' (i.e. are dismissed for cause or bad performance, or other circumstances determined by the Board to constitute a bad leaver) any vested but unexercised options or performance rights lapse. In each instance (good leaver or bad leaver) any unvested shares, options or performance rights lapse or are otherwise forfeited.

The Board also has discretion as to whether the relevant participant/nominee is to be considered a 'good leaver' or a 'bad leaver', if the Board determines that the relevant circumstances warrant such treatment.

7. Change of Control Event


If a change of control event occurs (which includes an unconditional takeover bid, a merger resulting in shareholders holding less than 50% of the Company, or a sale of a majority in value of the assets of the AnteoTech group), then subject to the Listing Rules, all unvested shares, unvested options and unvested performance rights held by participants will automatically vest and become immediately exercisable, in accordance with the Incentive Plan.

8. Amendment of Rules

Subject to the ASX Listing Rules, the Rules of the Equity Incentive Plan can be revoked, varied or amended by the Board from time to time.

LODGE YOUR VOTE


ONLINE

 <https://investorcentre.linkgroup.com>

BY MAIL

 AnteoTech Ltd
C/- Link Market Services Limited
Locked Bag A14
Sydney South NSW 1235 Australia

BY FAX

 +61 2 9287 0309

BY HAND

 Link Market Services Limited
Parramatta Square, Level 22, Tower 6,
10 Darcy Street, Parramatta NSW 2150

ALL ENQUIRIES TO

 Telephone: 1300 554 474 Overseas: +61 1300 554 474

LODGE A PROXY FORM

This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given above by **10:00am (Brisbane time) on Sunday, 12 November 2023**, being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting.

Proxy Forms may be lodged using the reply paid envelope or:



ONLINE

<https://investorcentre.linkgroup.com>

Login to the Link website using the holding details as shown on the Proxy Form. Select 'Voting' and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their "Holder Identifier" - Securityholder Reference Number (SRN) or Holder Identification Number (HIN).



BY MOBILE DEVICE

Our voting website is designed specifically for voting online. You can now lodge your proxy by scanning the QR code adjacent or enter the voting link <https://investorcentre.linkgroup.com> into your mobile device. Log in using the Holder Identifier and postcode for your shareholding.

To scan the code you will need a QR code reader application which can be downloaded for free on your mobile device.

QR Code



HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM

YOUR NAME AND ADDRESS

This is your name and address as it appears on the Company's share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. **Please note: you cannot change ownership of your shares using this form.**

APPOINTMENT OF PROXY

If you wish to appoint the Chairman of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chairman of the Meeting as your proxy, please write the name of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company.

DEFAULT TO CHAIRMAN OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chairman of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chairman of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel (KMP).

VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT

You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF A SECOND PROXY

You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company's share registry or you may copy this form and return them both together.

To appoint a second proxy you must:

- on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and
- return both forms together.

SIGNING INSTRUCTIONS

You must sign this form as follows in the spaces provided:

Individual: where the holding is in one name, the holder must sign.

Joint Holding: where the holding is in more than one name, either shareholder may sign.

Power of Attorney: to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the *Corporations Act 2001*) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate "Certificate of Appointment of Corporate Representative" must be produced prior to admission in accordance with the Notice of Meeting. A form of the certificate may be obtained from the Company's share registry or online at www.linkmarketservices.com.au.

**IF YOU WOULD LIKE TO ATTEND AND VOTE AT THE ANNUAL GENERAL MEETING, PLEASE BRING THIS FORM WITH YOU.
THIS WILL ASSIST IN REGISTERING YOUR ATTENDANCE.**

NAME SURNAME
ADDRESS LINE 1
ADDRESS LINE 2
ADDRESS LINE 3
ADDRESS LINE 4
ADDRESS LINE 5
ADDRESS LINE 6



X99999999999

PROXY FORM

I/We being a member(s) of AnteoTech Ltd and entitled to attend and vote hereby appoint:

APPOINT A PROXY

☐ the Chairman of the Meeting (mark box)

OR if you are **NOT** appointing the Chairman of the Meeting as your proxy, please write the name of the person or body corporate you are appointing as your proxy

or failing the person or body corporate named, or if no person or body corporate is named, the Chairman of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the **10:00am (Brisbane time) on Tuesday, 14 November 2023 at Rydges South Bank, Room Rooftop South, Level Twelve, 9 Glenelg Street, South Brisbane** (the Meeting) and at any postponement or adjournment of the Meeting.

Important for Resolutions 1, 3, 4a – 4d and 5a – 5e: If the Chairman of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chairman of the Meeting to exercise the proxy in respect of Resolutions 1, 3, 4a – 4d and 5a – 5e, even though the Resolutions are connected directly or indirectly with the remuneration of a member of the Company's Key Management Personnel (KMP).

The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business.

VOTING DIRECTIONS

Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting. Please read the voting instructions overleaf before marking any boxes with an ☒.

Resolutions

	For	Against	Abstain*		For	Against	Abstain*
1 Remuneration Report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	5b Grant of long term incentive Options to Director – Ewen Crouch	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2a Re-election of Director - Glenda McLoughlin	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	5c Grant of long term incentive Options to Director – Geoff Cumming	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2b Re-election of Director – Katherine Woodthorpe	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	5d Grant of long term incentive Options to Director – Glenda McLoughlin	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3 Grant of short term incentive Performance Rights under the Company's Equity Incentive Plan to the Managing Director & Chief Executive Officer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	5e Grant of long term incentive Options to Director – Katherine Woodthorpe	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4a Grant of attaching Options under the Share Purchase Plan to Director - Ewen Crouch	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	6 Ratification of prior issue of Placement Options under Listing Rule 7.1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4b Grant of attaching Options under the Share Purchase Plan to Director - David Radford	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7 Ratification of prior issue of Placement Shares under Listing Rule 7.1A	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4c Grant of attaching Options under the Share Purchase Plan to Director - Geoffrey Cumming	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8 Ratification of prior issue of SPP Shares under Listing Rule 7.1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4d Grant of attaching Options under the Share Purchase Plan to Director - Glenda McLoughlin	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	9 Ratification of prior issue of SPP Options under Listing Rule 7.1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5a Grant of long term incentive Options to Director – David Radford	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10 Approval of 10% Placement Facility	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



* If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your votes will not be counted in computing the required majority on a poll.

SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED

Shareholder 1 (Individual)

Sole Director and Sole Company Secretary

Joint Shareholder 2 (Individual)

Director/Company Secretary (Delete one)

Joint Shareholder 3 (Individual)

Director

This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder's attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company's constitution and the *Corporations Act 2001* (Cth).

ADO PRX2301N